Skip to main content
TipRanks
Go Ultimate75% OFF

Glenmark Pharmaceuticals Limited (GLENMARK) Stock Statistics & Valuation Metrics

5 Followers

Total Valuation

Glenmark Pharmaceuticals Limited has a market cap or net worth of INR 745.92B. The enterprise value is INR 653.53B.

Market Cap
INR 745.92B
Enterprise Value
INR 653.53B

Share Statistics

Glenmark Pharmaceuticals Limited has 282,224,670 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
282,224,670
Owned by Insiders
―
Owned by Institutions
8.41%

Financial Efficiency

Glenmark Pharmaceuticals Limited’s return on equity (ROE) is 0.13 and return on invested capital (ROIC) is 20.12%.

Return on Equity (ROE)
0.13
Return on Assets (ROA)
0.07
Return on Invested Capital (ROIC)
20.12%
Return on Capital Employed (ROCE)
0.30
Revenue Per Employee
10.02M
Profits Per Employee
803.64K
Employee Count
16,946
Asset Turnover
0.85
Inventory Turnover
2.59

Valuation Ratios

The current PE Ratio of Glenmark Pharmaceuticals Limited is 51.33. Glenmark Pharmaceuticals Limited’s PEG ratio is 1.17.

PE Ratio
51.33
PS Ratio
4.70
PB Ratio
6.64
Price to FCF
31.91
Price to Operating Cash Flow
26.27
PEG Ratio
1.17

Income Statement

In the last 12 months, Glenmark Pharmaceuticals Limited had revenue of 169.83B and earned 13.62B in profits. Earnings per share was 48.26.

Revenue
169.83B
Gross Profit
80.84B
Operating Income
39.99B
Pretax Income
19.85B
Net Income
13.62B
EBITDA
27.67B
Earnings Per Share (EPS)
48.26

Cash Flow

In the last 12 months, operating cash flow was 28.36B and capital expenditures -5.00B, giving a free cash flow of 23.35B billion.

Operating Cash Flow
28.36B
Free Cash Flow
23.35B
Free Cash Flow per Share
82.78

Dividends & Yields

Glenmark Pharmaceuticals Limited pays an annual dividend of INR 2.50, resulting in a dividend yield of 0.19%

Dividend Per Share
INR 2.50
Dividend Yield
0.19%
Payout Ratio
11.28%
Free Cash Flow Yield
3.13%
Earnings Yield
1.95%

Stock Price Statistics

Beta
0.72
52-Week Price Change
40.85%
50-Day Moving Average
2376.75
200-Day Moving Average
2264.12
Relative Strength Index (RSI)
70.71
Average Volume (3m)
24.97K

Important Dates

Glenmark Pharmaceuticals Limited upcoming earnings date is Feb 05, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 05, 2026
Next Earnings Date
Feb 05, 2027
Ex-Dividend Date
Oct 03, 2025

Financial Position

Glenmark Pharmaceuticals Limited as a current ratio of 1.77, with Debt / Equity ratio of 5.65%

Current Ratio
1.77
Quick Ratio
1.23
Debt to Market Cap
0.00
Net Debt to EBITDA
-0.21
Interest Coverage Ratio
19.16

Taxes

In the past 12 months, Glenmark Pharmaceuticals Limited has paid 6.23B in taxes.

Income Tax
6.23B
Effective Tax Rate
0.31

Enterprise Valuation

Glenmark Pharmaceuticals Limited EV to EBITDA ratio is 27.03, with an EV/FCF ratio of 31.96.

EV to Sales
4.71
EV to EBITDA
27.03
EV to Free Cash Flow
31.96
EV to Operating Cash Flow
26.32

Balance Sheet

Glenmark Pharmaceuticals Limited has INR 11.76B in cash and marketable securities with INR 5.94B in debt, giving a net cash position of INR 5.83B billion.

Cash & Marketable Securities
INR 11.76B
Total Debt
INR 5.94B
Net Cash
INR 5.83B
Net Cash Per Share
INR 20.65
Tangible Book Value Per Share
INR 283.66

Margins

Gross margin is 48.52%, with operating margin of 16.69%, and net profit margin of 9.16%.

Gross Margin
48.52%
Operating Margin
16.69%
Pretax Margin
12.01%
Net Profit Margin
9.16%
EBITDA Margin
17.42%
EBIT Margin
13.28%

Analyst Forecast

The average price target for Glenmark Pharmaceuticals Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target
―
Price Target Upside
―
Analyst Consensus
―
Analyst Count
―
Revenue Growth Forecast
-0.11%
EPS Growth Forecast
43.72%

Scores

Smart Score
―
AI Score
66